# Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children

> **NCT00840801** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 302 (actual)

## Conditions studied

- Encephalitis, Tick-Borne

## Interventions

- **BIOLOGICAL:** Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- **BIOLOGICAL:** Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)

## Key facts

- **NCT ID:** NCT00840801
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02-06
- **Primary completion:** 2010-05-20
- **Final completion:** 2010-05-20
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2024-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00840801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00840801, "Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00840801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*